Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Unicycive Therapeutics, Inc. See All Filings	D	2024-03-20 17:09:44 UTC
Amount To Be Raised $50,000,000 Associated Brokers / Dealers Leerink Partners LLC and Piper Sandler & Co. CIK Number 0001766140 Filed Document 0001213900-24-024422 Exclusions or Exemptions 506b Accepted Date 2024-03-20 17:09:44 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Unicycive Therapeutics, Inc. See All Filings	D	2023-03-13 16:46:09 UTC
Amount To Be Raised $30,190,000 Associated Brokers / Dealers EF Hutton, division of Benchmark Investments LLC CIK Number 0001766140 Filed Document 0001213900-23-019602 Exclusions or Exemptions 506b Accepted Date 2023-03-13 16:46:09 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Unicycive Therapeutics, Inc. See All Filings	D	2020-06-03 17:17:52 UTC
Amount To Be Raised $604,140 Associated Brokers / Dealers N/A CIK Number 0001766140 Filed Document 0001213900-20-014033 Exclusions or Exemptions 506b Accepted Date 2020-06-03 17:17:52 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Unicycive Therapeutics, Inc. See All Filings	D	2019-08-16 16:45:56 UTC
Amount To Be Raised $526,950 Associated Brokers / Dealers N/A CIK Number 0001766140 Filed Document 0001213900-19-016191 Exclusions or Exemptions 506b Accepted Date 2019-08-16 16:45:56 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
Unicycive Therapeutics, Inc. See All Filings	D	2019-03-04 16:19:17 UTC
Amount To Be Raised $420,000 Associated Brokers / Dealers N/A CIK Number 0001766140 Filed Document 0001213900-19-003518 Exclusions or Exemptions 506b Accepted Date 2019-03-04 16:19:17 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity